Teresa Lambe

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1298550/publications.pdf

Version: 2024-02-01

123 papers	26,794 citations	20817 60 h-index	17105 122 g-index
159 all docs	159 docs citations	159 times ranked	31212 citing authors

#	Article	IF	Citations
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111.	13.7	3,887
2	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, The, 2020, 396, 467-478.	13.7	2,080
3	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, The, 2020, 396, 1979-1993.	13.7	1,196
4	Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. New England Journal of Medicine, 2021, 384, 1885-1898.	27.0	1,077
5	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891.	13.7	979
6	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell, 2021, 184, 2348-2361.e6.	28.9	936
7	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine, 2021, 27, 2032-2040.	30.7	900
8	ChAdOx1ÂnCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature, 2020, 586, 578-582.	27.8	840
9	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell, 2022, 185, 467-484.e15.	28.9	788
10	A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature, 2005, 435, 452-458.	27.8	777
11	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell, 2021, 184, 4220-4236.e13.	28.9	630
12	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, The, 2021, 397, 1351-1362.	13.7	540
13	Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell, 2022, 185, 2422-2433.e13.	28.9	532
14	Antibody evasion by the P.1 strain of SARS-CoV-2. Cell, 2021, 184, 2939-2954.e9.	28.9	519
15	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet, The, 2021, 398, 2258-2276.	13.7	519
16	DNA repair is limiting for haematopoietic stem cells during ageing. Nature, 2007, 447, 686-690.	27.8	475
17	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine, 2021, 27, 270-278.	30.7	473
18	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell, 2021, 184, 2201-2211.e7.	28.9	442

#	Article	IF	Citations
19	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet, The, 2021, 398, 856-869.	13.7	430
20	Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1. Clinical Infectious Diseases, 2011, 52, 1-7.	5.8	424
21	Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet, The, 2022, 399, 234-236.	13.7	318
22	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet, The, 2022, 399, 521-529.	13.7	314
23	A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. New England Journal of Medicine, 2016, 374, 1635-1646.	27.0	295
24	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nature Medicine, 2021, 27, 279-288.	30.7	265
25	Seroprevalence of antiâ€“SARS-CoV-2 IgG antibodies in Kenyan blood donors. Science, 2021, 371, 79-82.	12.6	247
26	Dock8 mutations cripple B cell immunological synapses, germinal centers and long-lived antibody production. Nature Immunology, 2009, 10, 1283-1291.	14.5	236
27	Preliminary Assessment of the Efficacy of a T-Cellâ€“Based Influenza Vaccine, MVA-NP+M1, in Humans. Clinical Infectious Diseases, 2012, 55, 19-25.	5.8	224
28	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet, The, 2021, 398, 981-990.	13.7	214
29	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV,the, 2021, 8, e474-e485.	4.7	190
30	Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens. Nature Biotechnology, 2012, 30, 883-888.	17.5	189
31	Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infectious Diseases, The, 2020, 20, 816-826.	9.1	182
32	Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. Science Translational Medicine, 2021, 13, .	12.4	180
33	DOCK8 deficiency impairs CD8 T cell survival and function in humans and mice. Journal of Experimental Medicine, 2011, 208, 2305-2320.	8.5	175
34	Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens. Molecular Therapy, 2014, 22, 668-674.	8.2	165
35	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet, The, 2022, 399, 36-49.	13.7	161
36	Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else?. Experimental Dermatology, 2008, 17, 139-140.	2.9	148

#	Article	IF	Citations
37	Viral vectors as vaccine platforms: from immunogenicity to impact. Current Opinion in Immunology, 2016, 41, 47-54.	5.5	137
38	ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine, 2017, 35, 3780-3788.	3.8	133
39	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV,the, 2021, 8, e568-e580.	4.7	124
40	Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. Npj Vaccines, 2020, 5, 69.	6.0	121
41	Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine. ACS Central Science, 2021, 7, 594-602.	11.3	118
42	Cellular and developmental aspects of androgenetic alopecia. Experimental Dermatology, 1998, 7, 235-248.	2.9	117
43	Immune privilege or privileged immunity?. Mucosal Immunology, 2008, 1, 372-381.	6.0	111
44	Themis is a member of a new metazoan gene family and is required for the completion of thymocyte positive selection. Nature Immunology, 2009, 10, 831-839.	14.5	108
45	A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years. PLoS ONE, 2012, 7, e48322.	2.5	107
46	DOCK8 is essential for Tâ€cell survival and the maintenance of CD8⁺ Tâ€cell memory. European Journal of Immunology, 2011, 41, 3423-3435.	2.9	105
47	Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell, 2022, 185, 2116-2131.e18.	28.9	105
48	Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. Nature Communications, 2021, 12, 2893.	12.8	104
49	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nature Communications, 2021, 12, 2055.	12.8	102
50	Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults. EBioMedicine, 2018, 29, 146-154.	6.1	100
51	A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques. Science Advances, 2020, 6, eaba8399.	10.3	89
52	High Glucose-altered Gene Expression in Mesangial Cells. Journal of Biological Chemistry, 2002, 277, 9707-9712.	3.4	88
53	MAIT cell activation augments adenovirus vector vaccine immunogenicity. Science, 2021, 371, 521-526.	12.6	88
54	The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world. Immunology, 2020, 160, 223-232.	4.4	86

#	Article	IF	Citations
55	Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model. Npj Vaccines, 2017, 2, 28.	6.0	81
56	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike proteinâ€“specific T _H 1 response with a diverse TCR repertoire. Science Translational Medicine, 2021, 13, eabj7211.	12.4	80
57	Identification of a Steap3 endosomal targeting motif essential for normal iron metabolism. Blood, 2009, 113, 1805-1808.	1.4	75
58	CD4 T Cell-Dependent Autoimmunity against a Melanocyte Neoantigen Induces Spontaneous Vitiligo and Depends upon Fas-Fas Ligand Interactions. Journal of Immunology, 2006, 177, 3055-3062.	0.8	74
59	CD4+ T Follicular Helper Cells in Human Tonsils and Blood Are Clonally Convergent but Divergent from Non-Tfh CD4+ Cells. Cell Reports, 2020, 30, 137-152.e5.	6.4	74
60	Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels. Scientific Reports, 2019, 9, 16292.	3.3	72
61	DOCK8 is critical for the survival and function of NKT cells. Blood, 2013, 122, 2052-2061.	1.4	68
62	Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1. Scientific Reports, 2013, 3, 1443.	3.3	67
63	What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins. EBioMedicine, 2016, 8, 277-290.	6.1	67
64	Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. Human Vaccines and Immunotherapeutics, 2017, 13, 3020-3032.	3.3	67
65	A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice. Med, 2021, 2, 243-262.e8.	4.4	62
66	Limited Peripheral T Cell Anergy Predisposes to Retinal Autoimmunity. Journal of Immunology, 2007, 178, 4276-4283.	0.8	54
67	MyD88â€dependent autoimmune disease in Lynâ€deficient mice. European Journal of Immunology, 2007, 37, 2734-2743.	2.9	54
68	ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7. Nature Communications, 2021, 12, 5868.	12.8	52
69	Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge. Frontiers in Immunology, 2019, 10, 2005.	4.8	48
70	ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets. Npj Vaccines, 2021, 6, 67.	6.0	47
71	CITED1 homozygous null mice display aberrant pubertal mammary ductal morphogenesis. Oncogene, 2006, 25, 1532-1542.	5.9	46
72	A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters. PLoS Neglected Tropical Diseases, 2019, 13, e0007462.	3.0	46

#	Article	IF	Citations
73	Improved adjuvanting of seasonal influenza vaccines: Preclinical studies of <scp>MVAâ€NP+M</scp>1 coadministration with inactivated influenza vaccine. European Journal of Immunology, 2013, 43, 1940-1952.	2.9	43
74	Vaccine platforms for the prevention of Lassa fever. Immunology Letters, 2019, 215, 1-11.	2.5	43
75	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.. Journal of Infection, 2022, 84, 795-813.	3.3	43
76	Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya. Nature Communications, 2021, 12, 3966.	12.8	40
77	Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. PLoS Pathogens, 2021, 17, e1009804.	4.7	39
78	Manufacturing a chimpanzee adenovirusâ€vectored SARSâ€CoVâ€2 vaccine to meet global needs. Biotechnology and Bioengineering, 2022, 119, 48-58.	3.3	38
79	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. Nature Communications, 2021, 12, 5861.	12.8	38
80	Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7). SSRN Electronic Journal, 0, , .	0.4	36
81	Clinical Advances in Viral-Vectored Influenza Vaccines. Vaccines, 2018, 6, 29.	4.4	35
82	A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?. Philosophical Transactions of the Royal Society B: Biological Sciences, 2017, 372, 20160295.	4.0	33
83	Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice. Vaccine, 2019, 37, 5567-5577.	3.8	33
84	Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases. Lancet Infectious Diseases, The, 2015, 15, 356-359.	9.1	32
85	A naturally protective epitope of limited variability asÂan influenza vaccine target. Nature Communications, 2018, 9, 3859.	12.8	32
86	Hyper IgE in New Zealand black mice due to a dominant-negative CD23 mutation. Immunogenetics, 2004, 56, 564-571.	2.4	31
87	Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells. Journal of Experimental Medicine, 2020, 217, .	8.5	31
88	ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge. Npj Vaccines, 2021, 6, 32.	6.0	30
89	HLA-E: exploiting pathogen-host interactions for vaccine development. Clinical and Experimental Immunology, 2019, 196, 167-177.	2.6	28
90	Viral vector vaccines. Current Opinion in Immunology, 2022, 77, 102210.	5.5	28

#	Article	IF	Citations
91	Measuring Cellular Immunity to Influenza: Methods of Detection, Applications and Challenges. Vaccines, 2015, 3, 293-319.	4.4	26
92	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. JCI Insight, 2022, 7, .	5.0	26
93	Spontaneous B cell hyperactivity in autoimmune-prone MRL mice. International Immunology, 2006, 18, 1127-1137.	4.0	24
94	The Essential Role of DOCK8 in Humoral Immunity. Disease Markers, 2010, 29, 141-150.	1.3	24
95	Novel Viral Vectored Vaccines for the Prevention of Influenza. Molecular Medicine, 2012, 18, 1153-1160.	4.4	24
96	Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. JCI Insight, 2022, 7, .	5.0	24
97	B-cell Tolerance. Transplantation, 2006, 81, 308-315.	1.0	23
98	T-Cell Responses in Children to Internal Influenza Antigens, 1 Year After Immunization With Pandemic H1N1 Influenza Vaccine, and Response to Revaccination With Seasonal Trivalentâ€“inactivated Influenza Vaccine. Pediatric Infectious Disease Journal, 2012, 31, e86-e91.	2.0	23
99	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. EBioMedicine, 2022, 77, 103902.	6.1	23
100	Expression and Cellular Immunogenicity of a Transgenic Antigen Driven by Endogenous Poxviral Early Promoters at Their Authentic Loci in MVA. PLoS ONE, 2012, 7, e40167.	2.5	22
101	Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques. Science Advances, 2021, 7, eabg7996.	10.3	20
102	Divergent trajectories of antiviral memory after SARS-CoV-2 infection. Nature Communications, 2022, 13, 1251.	12.8	20
103	The Threshold of Protection from Liver-Stage Malaria Relies on a Fine Balance between the Number of Infected Hepatocytes and Effector CD8+ T Cells Present in the Liver. Journal of Immunology, 2017, 198, 2006-2016.	0.8	17
104	Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral and Cellular Immune Responses Conferring Protection against Stringent Influenza A Virus Challenge. Journal of Immunology, 2017, 199, 1333-1341.	0.8	16
105	Modified Vaccinia Ankaraâ€“Vectored Vaccine Expressing Nucleoprotein and Matrix Protein 1 (M1) Activates Mucosal M1-Specific T-Cell Immunity and Tissue-Resident Memory T Cells in Human Nasopharynx-Associated Lymphoid Tissue. Journal of Infectious Diseases, 2020, 222, 807-819.	4.0	16
106	ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models. Communications Biology, 2021, 4, 915.	4.4	15
107	Detection of Vaccine-Induced Antibodies to Ebola Virus in Oral Fluid. Open Forum Infectious Diseases, 2016, 3, ofw031.	0.9	13
108	Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines. Vaccine, 2016, 34, 1688-1695.	3.8	13

#	Article	IF	Citations
109	Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter. Vaccine, 2016, 34, 49-55.	3.8	13
110	A Multi-Filovirus Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector. Vaccines, 2020, 8, 241.	4.4	12
111	The essential role of DOCK8 in humoral immunity. Disease Markers, 2010, 29, 141-50.	1.3	12
112	Differential expression of connexin 43 in mouse mammary cells. Cell Biology International, 2006, 30, 472-479.	3.0	10
113	Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine. SSRN Electronic Journal, 0, , .	0.4	10
114	The Integration of Human and Veterinary Studies for Better Understanding and Management of Crimean-Congo Haemorrhagic Fever. Frontiers in Immunology, 2021, 12, 629636.	4.8	8
115	Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility. Journal of Virological Methods, 2022, 302, 114475.	2.1	8
116	An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females. EBioMedicine, 2022, 81, 104128.	6.1	8
117	Recombinant protein vaccines against SARS-CoV-2. Lancet Infectious Diseases, The, 2021, 21, 1337-1338.	9.1	6
118	CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination. JCI Insight, 2022, 7, .	5.0	6
119	Respiratory and Intramuscular Immunization With ChAdOx2-NPM1-NA Induces Distinct Immune Responses in H1N1pdm09 Pre-Exposed Pigs. Frontiers in Immunology, 2021, 12, 763912.	4.8	5
120	Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity. SSRN Electronic Journal, 0, , .	0.4	2
121	Why do breakthrough COVID-19 infections occur in the vaccinated?. QJM - Monthly Journal of the Association of Physicians, 2022, 115, 67-68.	0.5	2
122	Commmentary 7. Experimental Dermatology, 2008, 17, 157-158.	2.9	0
123	Response to Letter to the Editor by Ish et al. entitled â€˜COVID-19 vaccine equityâ€”the need of the hourâ€™. QJM - Monthly Journal of the Association of Physicians, 2022, , .	0.5	0